Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered blood vessel could simplify dialysis for kidney patients

NCT ID NCT03183245

First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 28 times

Summary

This phase 3 trial tested a lab-grown blood vessel (Human Acellular Vessel, or HAV) against the standard surgically created fistula in 242 people with end-stage kidney disease on hemodialysis. The goal was to see which option works better for providing reliable access to filter blood. The study measured how well each access type functioned at 6 months and how long it lasted without being abandoned.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alliance Research

    Laguna Hills, California, 92653, United States

  • Arizona Kidney Disease and Hypertension Center (AKDHC)

    Phoenix, Arizona, 85012, United States

  • Balboa Nephrology

    San Diego, California, 92123, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Coastal Vascular & Interventional, PLLC

    Pensacola, Florida, 32503, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Denver Health Medical Center

    Denver, Colorado, 80204, United States

  • Grady Memorial Hospital

    Atlanta, Georgia, 30303, United States

  • Huntington Hospital

    Pasadena, California, 91105, United States

  • Kaiser Permanente Sunnsyide

    Portland, Oregon, 97015, United States

  • Kidney Care & Transplant Services of New England

    West Springfield, Massachusetts, 01089, United States

  • Memorial Healthcare System

    Pembroke Pines, Florida, 33021, United States

  • Mills Peninsula Hospital

    San Mateo, California, 94401, United States

  • Olive View- UCLA Medical Center

    Sylmar, California, 91342, United States

  • Overlook Medical Center

    Summit, New Jersey, 07901, United States

  • Rutgers University

    Newark, New Jersey, 07103, United States

  • South Plains Surgery Center

    Lubbock, Texas, 79416, United States

  • Surgical Specialists of Charlotte

    Charlotte, North Carolina, 28207, United States

  • Tampa General Hospital

    Tampa, Florida, 33606, United States

  • The Regional Medical Center

    Orangeburg, South Carolina, 29118, United States

  • The Vascular Experts

    Darien, Connecticut, 06820, United States

  • UC Davis

    Sacramento, California, 95817, United States

  • United Surgical Associates

    Lexington, Kentucky, 40504, United States

  • University of Arizona

    Tucson, Arizona, 85724, United States

  • University of CA, San Diego - LaJolla VA Hospital

    La Jolla, California, 92161, United States

  • University of California San Diego, Jacobs Medical Center

    La Jolla, California, 92103, United States

  • University of California, Irvine

    Irvine, California, 92868, United States

  • University of Southern California

    Los Angeles, California, 90033, United States

  • University of Tennessee Knoxville

    Knoxville, Tennessee, 37920, United States

  • VA Long Beach Healthcare System

    Long Beach, California, 90822, United States

  • VA Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Human Acellular Vessel (HAV)

What this could lead to

If it works, this could provide a reliable, ready-to-use option for dialysis access, reducing the need for multiple surgeries.

What could go wrong

This is a completed phase 3 trial, but the HAV may not work as well as a natural fistula for everyone, and there are risks of infection or blockage.

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.